Systemic Treatment Versus No Systemic Treatment After Biliary Drainage in Patients with Icteric Hepatocellular Carcinoma: A Retrospective Cohort Study.
- 1Department of Gastroenterology and Hepatology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
- 2College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
Abstract
Background/Objectives: Icteric hepatocellular carcinoma (HCC) is characterized by obstructive jaundice, impaired liver function, and limited treatment options. Biliary drainage may relieve jaundice and permit subsequent anticancer therapy, but the clinical benefit of systemic treatment remains uncertain in this setting. Methods: This retrospective, single-center cohort study included 78 patients with icteric HCC who underwent biliary drainage via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangial drainage (PTCD). Thirty patients received systemic treatment during the treatment course surrounding biliary drainage (five initiated treatment before drainage and 25 on or after drainage), whereas 48 did not receive systemic treatment. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier analysis and Cox regression. Propensity score matching (PSM), time-dependent Cox regression, and a 42-day landmark analysis were performed as sensitivity analyses. Results: Median OS was longer with systemic treatment than without systemic treatment (14.6 vs. 6.7 months; p = 0.025), as was PFS (7.5 vs. 3.5 months; p = 0.005). After 1:1 PSM, systemic therapy remained associated with longer PFS (7.6 vs. 4.6 months; p = 0.044), whereas the OS difference was not statistically significant. In time-dependent analyses, systemic treatment was not significantly associated with OS (HR, 0.70; 95% CI, 0.40-1.22; p = 0.207) or PFS (HR, 0.65; 95% CI, 0.38-1.13; p = 0.128). Conclusions: Systemic treatment was associated with favorable outcomes in selected patients in the primary analyses, but these associations were attenuated after accounting for treatment timing. The findings are exploratory and do not establish a causal treatment effect.
Related
- Treatment-Stratified Immune–Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy
- The Efficacy and Safety of Combined Locoregional and Systemic Therapy versus Systemic Therapy Alone in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: A Multicenter Real-World Retrospective Cohort Study.
- Integrating Magnetic Resonance Imaging-Based Deep Learning and Radiomics to Predict Treatment Response in Hepatocellular Carcinoma Receiving Combined Systemic and Locoregional Therapies: A Multicenter Study.
- Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization as First-Line Treatment for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma: A Nationwide Multicenter Retrospective Study.
- Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design
BibTeX
@article{liu2026systemic,
title = {{Systemic Treatment Versus No Systemic Treatment After Biliary Drainage in Patients with Icteric Hepatocellular Carcinoma: A Retrospective Cohort Study.}},
author = {Chung-Wei Liu and Chi-Huan Wu and Yung-Kuan Tsou and Mu-Hsien Lee and Kai-Feng Sung and Cheng-Hui Lin},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193138},
url = {https://europepmc.org/article/MED/42882833},
note = {CC BY},
}
RIS
TY - JOUR
TI - Systemic Treatment Versus No Systemic Treatment After Biliary Drainage in Patients with Icteric Hepatocellular Carcinoma: A Retrospective Cohort Study.
AU - Chung-Wei Liu
AU - Chi-Huan Wu
AU - Yung-Kuan Tsou
AU - Mu-Hsien Lee
AU - Kai-Feng Sung
AU - Cheng-Hui Lin
PY - 2026
DA - 2026/09/28
JO - Cancers
DO - 10.3390/cancers18193138
UR - https://europepmc.org/article/MED/42882833
AB - Background/Objectives: Icteric hepatocellular carcinoma (HCC) is characterized by obstructive jaundice, impaired liver function, and limited treatment options. Biliary drainage may relieve jaundice and permit subsequent anticancer therapy, but the clinical benefit of systemic treatment remains uncertain in this setting. Methods: This retrospective, single-center cohort study included 78 patients with icteric HCC who underwent biliary drainage via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangial drainage (PTCD). Thirty patients received systemic treatment during the treatment course surrounding biliary drainage (five initiated treatment before drainage and 25 on or after drainage), whereas 48 did not receive systemic treatment. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier analysis and Cox regression. Propensity score matching (PSM), time-dependent Cox regression, and a 42-day landmark analysis were performed as sensitivity analyses. Results: Median OS was longer with systemic treatment than without systemic treatment (14.6 vs. 6.7 months; p = 0.025), as was PFS (7.5 vs. 3.5 months; p = 0.005). After 1:1 PSM, systemic therapy remained associated with longer PFS (7.6 vs. 4.6 months; p = 0.044), whereas the OS difference was not statistically significant. In time-dependent analyses, systemic treatment was not significantly associated with OS (HR, 0.70; 95% CI, 0.40-1.22; p = 0.207) or PFS (HR, 0.65; 95% CI, 0.38-1.13; p = 0.128). Conclusions: Systemic treatment was associated with favorable outcomes in selected patients in the primary analyses, but these associations were attenuated after accounting for treatment timing. The findings are exploratory and do not establish a causal treatment effect.
SN - 2072-6694
ER -